XTSXTELO
Market cap6mUSD
Dec 30, Last price
0.13CAD
1D
8.33%
1Q
-7.14%
Jan 2017
-97.14%
IPO
-93.16%
Name
Telo Genomics Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
40.10%
Rev. gr., 5y
%
Revenues
0k
Net income
-3m
L-3.82%
CFO
-2m
L-6.48%
Earnings
Feb 25, 2025
Profile
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 1,364 | 2,854 | 2,167 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,364) | (2,854) | (2,167) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 10 | (5) | (5) | ||||||
Tax Rate | |||||||||
NOPAT | (1,374) | (2,849) | (2,162) | ||||||
Net income | (2,713) -3.82% | (2,821) 33.66% | (2,110) 97.25% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 610 | 2,834 | 195 | ||||||
BB yield | -4.62% | -15.97% | -0.93% | ||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | 32 | 40 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (796) | (2,641) | (2,653) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (2,459) | (2,630) | (1,795) | ||||||
CAPEX | (5) | (69) | (25) | ||||||
Cash from investing activities | (5) | (69) | (25) | ||||||
Cash from financing activities | 587 | 2,679 | 877 | ||||||
FCF | (1,338) | (2,885) | (2,120) | ||||||
| Balance | |||||||||
Cash | 796 | 2,673 | 2,693 | ||||||
Long term investments | |||||||||
Excess cash | 796 | 2,673 | 2,693 | ||||||
Stockholders' equity | (5,483) | (3,389) | (3,192) | ||||||
Invested Capital | 6,073 | 6,034 | 5,835 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 71,384 | 60,152 | 58,661 | ||||||
Price | 0.19 -37.29% | 0.30 -17.48% | 0.36 -28.50% | ||||||
Market cap | 13,206 -25.58% | 17,745 -15.38% | 20,971 -10.55% | ||||||
EV | 12,410 | 15,104 | 18,318 | ||||||
EBITDA | (1,324) | (2,821) | (2,110) | ||||||
EV/EBITDA | |||||||||
Interest | 5 | 5 | 5 | ||||||
Interest/NOPBT | |||||||||